RED: Monotherapy for the first-line treatment of adults with blastic plasmacytoid dendritic cell neoplasm. (Decision date - February 2022)
Do Not Prescribe (DNP): NICE TA782 - Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) (Decision date - April 2022)